Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience

International Journal of Immunopathology and Pharmacology

Volumn 23, Issue 2, 2010, Pages 503-509

  Esposito, Maria ^a   Giunta, A ^a   Mazzotta, A ^a   Babino, G ^a   Talamonti, M ^a   Chimenti, M S ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

DLQI; Etanercept; PDI; Tumor necrosis factor alpha

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID DERIVATIVE; INFLIXIMAB; METHOTREXATE; RETINOID DERIVATIVE; STEROID; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; FEMALE; HAIR LOSS; HUMAN; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LONG TERM CARE; MALE; OPEN STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PUVA; QUALITY OF LIFE; SELF REPORT; SIDE EFFECT; SOLID TUMOR; TREATMENT DURATION; TUBERCULOSIS; URINARY TRACT INFECTION; URTICARIA; VERTIGO; WEIGHT GAIN;

EID: 77955370347     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201002300212     Document Type: Article

References (21)

1. Christophers E, Mrowietz U. Psoriasis In: Fitzpatrick's dermatology in general medicine. Freedberg IM, Eisen AZ, Wolff K, Frank Austen K, Goldsmith LA, Katz SI. 6th ed. McGraw Hill, New York. 2003; 407-27.
2. Naldi L. Epidemiology of psoriasis. Cur Drug Targets Inflamm Allergy 2004; 3:121-8.
3. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life; results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
4. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis. The contribution of clinical variables and psoriasis specific stress. Br J Dermatol 1997; 137:755-60.
5. Finlay AY, Coles EC. The effects of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132:236-44.
6. Gottlieb AB. Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances. J Investig Dermatol Symp Proc 2004; 9:79-83.
7. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK. Biology of tumor necrosis factor-α - implications for psoriasis. Exp Dermatol 2004; 13:193-222.
8. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90.
9. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-32.
10. Leonardi CL, Powers JL, Matheson RT, Goffe GS, Zitnik R, Wang A, Gottlieb AB. Etanercept psoriasis study group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
11. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157:238-44
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-6.
13. Lewis V, Finlay AY. 10 Years Experience of the Dermatology Life Quality Index (DLQI ). J Investig Dermatol Symp Proc 2004; 9:169-80.
14. Chren MM, Lasek RJ, Flocke SA, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133:1433-40.
15. Abeni D, Picardi A, et al. Further evidence of the validity and reliability of the skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology 2002; 204:43-9.
16. Finlay AY, Kelly SE. Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12:8-11.
17. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143:719-26.
18. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56:598-603.
19. Paller AS, Siegfried EC, Langley RG, et al: Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358:241-51.
20. Esposito M, Mazzotta A, Saraceno R, Schipani C, Chimenti S. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009; 22:219-25.
21. Dauden E, Griffiths CEM, Ortonne J-P, Kragballe K, Molta CT, Robertson D, Pedersen R, Estojak J, Boggs R. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol 2009; 23:1374-82.